Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Circulation

• Publication date

  1995-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.91.8.2132PMID 7697841
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Canadian Consensus Conference on Coronary Thrombolysis--1994 update.

  1994cited by this paper
• Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.

  1994cited by this paper
• Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

  1994cited by this paper
• Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.

  1994cited by this paper
• A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.

  1994cited by this paper
• A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.

  1994cited by this paper
• Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

  1994cited by this paper
• The development of hirudin as an antithrombotic drug.

  1994cited by this paper
• Science of urinary incontinence

  1994cited by this paper
• Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.

  1994cited by this paper
• The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

  1993cited by this paper
• Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis.

  1993cited by this paper
• Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II

  1992cited by this paper
• Combination of Inhibition of Thrombin and Blockade of Thromboxane A2 Synthetase and Receptors Enhances Thrombolysis and Delays Reocclusion in Canine Coronary Arteries

  1992cited by this paper
• The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model

  1992cited by this paper
• Relative Efficacy of Antithrombin Compared With Antiplatelet Agents in Accelerating Coronary Thrombolysis and Preventing Early Reocclusion

  1991cited by this paper
• Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.

  1990cited by this paper
• Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis.

  1990cited by this paper
• MEDICAL SCIENCE: GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction

  1990cited by this paper
• GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

  1990cited by this paper
• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

  1990cited by this paper
• Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.

  1990cited by this paper
• An on-line system for the quantitative analysis of coronary arterial segments

  1989cited by this paper
• Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

  1988cited by this paper
• Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase.

  1988cited by this paper
• Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

  1987cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

  1987cited by this paper
• Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.

  1985cited by this paper
• The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

  1985cited by this paper
• RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION: Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator

  1985cited by this paper
• The roles of protein C and thrombomodulin in the regulation of blood coagulation.

  1984cited by this paper

• Primary Percutaneous Coronary Intervention and Application of the Pharmacoinvasive Approach Within ST-Elevation Myocardial Infarction Care Networks: CJC Supplement - 40 Years of Innovation in Interventional Cardiology in Canada.

  2021cites this paper
• Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention

  2021cites this paper
• Fibrinolysis in Acute Myocardial Infarction ; State of the Art

  2018cites this paper
• Acute Myocardial Infarction Low Molecular Weight Heparin ( Dalteparin ) as Adjuvant Treatment to Thrombolysis in Acute Myocardial Infarction — A Pilot Study : Biochemical Markers in Acute Coronary Syndromes ( BIOMACS II )

  2016cites this paper
• Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future

  2015cites this paper
• Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes

  2015cites this paper
• Myocardial infarction and atrial fibrillation: different impact of anti-IIa vs anti-Xa new oral anticoagulants: a meta-analysis of the interventional trials.

  2015cites this paper
• Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials

  2015cites this paper
• Treatment of ST Elevation Myocardial Infarction from Fibrinolysis to Primary PCI: In Terms of Risks and Benefits

  2015cites this paper
• Recent Advances in Optimal Adjunctive Antithrombotic Therapy in STEMI Patients Undergoing Primary Angioplasty: An Overview.

  2015cites this paper
• Inverse association of the endogenous thrombin potential (ETP) with cardiovascular death: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.

  2014cites this paper
• 28 – Thrombolytic Therapy

  2013cites this paper
• Bivalirudin

  2012cites this paper
• Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition.

  2011cites this paper
• Antithrombin Therapy for Acute ST-Segment Elevation Myocardial Infarction

  2010cites this paper
• Use of Anticoagulants in ST-Segment Elevation Myocardial Infarction Patients; A Focus on Low-Molecular-Weight Heparin

  2008cites this paper
• Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction

  2008cites this paper
• Direct thrombin inhibitors in cardiac disease

  2007cites this paper
• Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology

  2007cites this paper
• Chapter 28 – Thrombolytic Therapy*

  2007cites this paper
• The Challenge of Defining Bleeding Among Patients with Acute Coronary Syndromes

  2007cites this paper
• Efficacy and Safety of Bivalirudin Versus Heparins in Reduction of Cardiac Outcomes in Acute Coronary Syndrome and Percutaneous Coronary Interventions

  2007cites this paper
• Clotting for the clinician: An overview of thrombosis and antithrombotic therapy

  2005cites this paper
• Bivalirudin: a review

  2005cites this paper
• Heparin in Interventional Radiology: A Therapy in Evolution

  2005cites this paper
• Potential for a new coronary thrombolytic plateau

  2004cites this paper
• Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator

  2004cites this paper
• Antithrombin Therapy in Acute Coronary Syndromes

  2004cites this paper
• Thrombolytic Therapy: The Treatment of Choice in Acute Myocardial Infarction

  2004cites this paper
• Bivalirudin: an anticoagulant option for percutaneous coronary intervention

  2004cites this paper
• A Randomized, Blinded Study of Two Doses of Novastan® (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan® and T-PA (MINT)

  2004cites this paper
• Adjunctive Use of Direct Thrombin Inhibitors in Patients Receiving Fibrinolytic Therapy for Acute Myocardial Infarction

  2004cites this paper
• Factor XII‐dependent increases in thrombin activity induce carboxypeptidase‐mediated attenuation of pharmacological fibrinolysis

  2004cites this paper
• Coronary Artery Patency and Survival in Clinical Trials

  2004cites this paper
• Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cites this paper
• Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin.

  2004cites this paper
• Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins

  2004cites this paper
• Enhancing thrombolysis with adjunctive therapy

  2004cites this paper
• Clinician Update: Direct Thrombin Inhibitors in Acute Coronary Syndromes

  2003cites this paper
• Current Developments in Antithrombotic Therapy: The Role of Antithrombin Agents

  2003cites this paper
• Construction and In Vitro Testing of a Novel Fab-Hirudin–Based Fusion Protein That Targets Fibrin and Inhibits Thrombin in a Factor Xa–Dependent Manner

  2003cites this paper
• Clinical Results with Direct Thrombin Inhibitors

  2003cites this paper
• Management of Acute Coronary Syndromes

  2003cites this paper
• Antiplatelet and Anticoagulant Therapy

  2003cites this paper
• Bivalirudin for the Treatment of Heparin-Induced Thrombocytopenia

  2003cites this paper
• The evolving role of direct thrombin inhibitors in acute coronary syndromes.

  2003cites this paper
• Thrombolytic therapy: clinical applications.

  2003cites this paper
• Thrombolytic Therapy

  2002cites this paper
• Bivalirudin: a direct thrombin inhibitor.

  2002cites this paper
• Bivalirudin: A Direct Thrombin Inhibitor for Percutaneous Transluminal Coronary Angioplasty

  2002cites this paper
• Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures

  2002cites this paper
• The Role of Antithrombin Agents and Factor Xa-Inhibitors in Antithrombotic Treatment.

  2002cites this paper
• Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial.

  2002cites this paper
• Antithrombotic agents in the treatment of severe sepsis

  2002cites this paper
• Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions

  2002cites this paper
• Antithrombotic Agents in the Management of Sepsis.

  2002cites this paper
• Drugs in development.

  2002cites this paper
• Pharmacology and Clinical Use of Bivalirudin

  2002cites this paper
• Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes

  2001cites this paper
• Bivalirudin: a new approach to anticoagulation.

  2001cites this paper
• Antithrombotic therapy in patients with acute coronary syndromes.

  2001cites this paper
• [Direct thrombin inhibitors: their role in the treatment of arterial and venous thrombosis].

  2001cites this paper
• AVANCES EN EL TRATAMIENTO ANTITROMBÓTICO

  2001cites this paper
• Intravenous thrombolysis in acute myocardial infarction.

  2001cites this paper
• Inhibidores directos de la trombina: su papel en el tratamiento de la trombosis arterial y venosa

  2001cites this paper
• Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary Syndromes: Observations From the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial

  2001cites this paper
• A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.

  2001cites this paper
• Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).

  2001cites this paper
• Emerging anticoagulant and thrombolytic drugs

  2001cites this paper
• Conjunctive therapy to reduce the occurrence of coronary reocclusion after thrombolytic treatment of AMI

  2001cites this paper
• Bivalirudin: a new generation antithrombotic drug

  2000cites this paper
• Coronary Thrombosis and Myocardial Infarction

  2000cites this paper
• Argatroban and Alteplase in Patients with Acute Myocardial Infarction: The ARGAMI Study

  2000cites this paper
• Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.

  2000cites this paper
• Medical treatment for acute coronary syndromes.

  2000cites this paper
• Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition.

  2000cites this paper
• Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials.

  1999cites this paper
• Clinical outcomes of bivalirudin for ischemic heart disease.

  1999cites this paper
• The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.

  1999cites this paper
• Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin.

  1999cites this paper
• Antithrombins and the importance of good control.

  1999cites this paper
• Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).

  1999cites this paper
• A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.

  1999influential citation
• Thrombolytic and Antithrombotic Therapies for Acute Coronary Syndromes

  1999cites this paper
• Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.

  1999cites this paper
• [Practice guidelines of the Spanish Society of Cardiology. Recommendations for the use of antithrombotic treatment in cardiology].

  1999cites this paper
• Clinical status of direct thrombin inhibitors.

  1999cites this paper
• Parenteral direct antithrombins

  1999cites this paper
• Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología

  1999cites this paper
• Antithrombotic therapy in acute coronary syndromes.

  1999cites this paper
• Novel Antithrombotic Strategies

  1998cites this paper
• Novel anticoagulants based on direct inhibition of thrombin and factor Xa.

  1998cites this paper
• A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators.

  1998cites this paper
• Optimización del tratamiento trombolítico en el infarto agudo de miocardio: papel de los nuevos fármacos fibrinoselectivos y de la asociación con los nuevos antitrombóticos

  1998cites this paper
• Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.

  1998influential citation
• New Agents, New Trials, New Solutions

  1998cites this paper
• Análise da utilização dos novos inibidores da trombina na prática médica

  1998cites this paper
• Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial.

  1998cites this paper
• [Optimization of thrombolytic treatment in acute myocardial infarct: the role of new fibrinoselective drugs and their combination with new antithrombotics].

  1998cites this paper
• Effective Use of BCH-2763, a New Potent Injectable Direct Thrombin Inhibitor, in Combination with Tissue Plasminogen Activator (tPA) in a Rat Arterial Thrombolysis Model

  1998cites this paper